focus -WSS

focus

author：explore 2025-08-23 04:57:11 - browse：2614

Sammy Kimball for STAT

Can Novavax finally get it right? What’s a “triple-G” drug? And is Novo Nordisk losing ground?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain how the era of Wegovy could be short-lived in light of powerful new weight-loss medicines from Eli Lilly. Then, John Jacobs, the new CEO of Novavax, stops by to explain his plan to right the ship at a company that has struggled to make the most of its potent Covid-19 vaccine.

For more on what we cover, here’s the news on Lilly; here’s more on Novavax; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Search called off for baby washed away in Pennsylvania flash flood

WSS

Study gives hint on South Asians’ higher risk of cardiovascular disease

UHS says company favors patients whose insurance pays more

What to watch for from Zogenix and Amicus clinical trials

Why patients can’t get everything they want on drug pricing

Resistance to opioid

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

focus

focus

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

Ebola vaccine can save some who are already sick, per new study

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Resistance to opioid

In age of alternative facts, a scholarly course on calling out crap

'Investigate these claims': UFO transparency at center of House hearing

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Russian fighter jet damages US Reaper drone with flare over Syria: Officials

Activists slam private health insurers over coverage restrictions

Democrats decry new health bill for going easy on private equity

hotspot

What causes rare myocarditis in young men after Covid vaccines?

Why don't Americans have at

Long Covid research funding gets a major boost from NIH

Study gives hint on South Asians’ higher risk of cardiovascular disease

UHS says company favors patients whose insurance pays more

How doctors’ personal politics affect patients

explore

leisure time

hotspot

explore